Safety

Product Photos

  • Tablet, Amlodipine 5 + Valsartan 160 + HCTZ 12.5
  • Tablet, Amlodipine 5 + Valsartan 160 + HCTZ 25
  • Tablet, Amlodipine 10 + Valsartan 160 + HCTZ 12.5
  • Tablet, Amlodipine 10 + Valsartan 160 + HCTZ 25
  • Tablet, Amlodipine 10 + Valsartan 320 + HCTZ 25
  • Label example, Torrent Amlodipine 5 + Valsartan 160 + HCTZ 12.5
  • Label example, Torrent Amlodipine 10 + Valsartan 160 + HCTZ 12.5
  • Label example, Torrent Amlodipine 10 + Valsartan 160 + HCTZ 25
  • Label example, Torrent Amlodipine 5 + Valsartan 160 + HCTZ 25
  • Label example, Torrent Amlodipine 10 + Valsartan 320 + HCTZ 25

Announcement

Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.

To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Valsartan is used to control high blood pressure and for the treatment of heart failure. In combination with amlodipine plus hydrochlorothiazide, it is used to control high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

The products subject to recall are listed below and packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

NDCProduct DescriptionLot/BatchExpiration Date
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2D025Nov-2019
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2D026Nov-2019
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2E001Jan-2020
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2E002Jan-2020
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2E003Jan-2020
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2E004Jan-2020
NDC 13668-325-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/320mg/25mg, 30 TabletsBBX2E005Jan-2020
NDC 13668-328-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/160mg/25mg, 30 TabletsBBX9D004Nov-2019
NDC 13668-328-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/160mg/25mg, 30 TabletsBBX9E001Jan-2020
NDC 13668-326-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 5mg/160mg/12.5mg, 30 TabletsBBY1E001Dec-2019
NDC 13668-326-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 5mg/160mg/12.5mg, 30 TabletsBBY1E003Mar-2020
NDC 13668-327-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10mg/160mg/12.5mg, 30 TabletsBBY2E001Mar-2020
NDC 13668-329-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 5mg/160mg/25mg, 30 TabletsBBY4D004Nov-2019
NDC 13668-329-30Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 5mg/160mg/25mg, 30 TabletsBBY4E001Jan-2020

Valsartan/Amlodipine/HCTZ tablets were distributed Nationwide to Torrent’s wholesale, distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:

  • 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).
  • Medinfo.Torrent@apcerls.com

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product please contact Qualanex at 1-800- 505-9291 (live calls received 8 am -5:30 pm Eastern Time).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

FDA Press Announcement

###



Source link